Morgan Stanley upgraded Halozyme (HALO) to Overweight from Equal Weight with a price target of $75, up from $62, post the Q2 sales beat. The company upped its fiscal 2025 guidance due to strong royalty revenues, the analyst tells investors in a research note. The firm says it now has higher conviction on Halozyme’s future growth trajectory and regulatory outlook.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Therapeutics Reports Strong Q2 2025 Results
- Positive Outlook and Strong Performance Drive Buy Rating for Halozyme
- Halozyme reports Q2 non-GAAP EPS $1.54, consensus $1.23
- Halozyme raises FY25 non-GAAP EPS view to $6.00-$6.40 from $5.30-$5.70
- Halozyme Therapeutics (HALO) Q2 Earnings Cheat Sheet